Project Grant K99NS136849
Award Date
12/1/24
Completion Date
11/30/26
Dollars Obligated
$124K
Federal Agency
National Institute of Neurological Disorders and Stroke
Federal Grant Program
93.853
Assistance Type
Project Grant
Place of Performance
Worcester, MA 01655, USA
Similar Awards
This Project Grant award of $1,106,142, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to identify mechanisms of neurofilament regulation and turnover in amyotrophic lateral sclerosis (ALS). The key objectives are to: 1) Develop advanced proteomic assays to analyze neurofilament isoforms and post-translational modifications in ALS, 2)...
This federal Project Grant award, valued at $129,717.00 and awarded on January 20, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to investigate the role of neutrophil heterogeneity and molecular mechanisms in driving amyotrophic lateral sclerosis (ALS). The research aims to identify subpopulations of neutrophils and associated mechanisms...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $645,391 to The Trustees of Columbia University in the City of New York to conduct research on the effects of re-expressing embryonic motor neuron selector transcription factors in mouse models of amyotrophic lateral sclerosis (ALS) and in ALS motor neurons derived from induced...
This Project Grant award of $374,349 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports the development and optimization of a new animal model for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The goal is to create a mouse model that accurately recapitulates the human disease spectrum by incorporating an acetylation-mimicking...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded Aquinnah Pharmaceuticals, Inc. a $1,499,212 Project Grant (CFDA 93.853 - Extramural Research Programs in the Neurosciences and Neurological Disorders) to develop a novel oral brain penetrant therapeutic for amyotrophic lateral sclerosis (ALS). The project aims to manufacture the therapeutic candidate, conduct IND-enabling studies, and engage in a pre-IND meeting with the FDA. The goal is to create the first effective...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) provides $460,625.00 to the University of Massachusetts Medical School (UMass Medical) from June 1, 2025 to May 31, 2027. The grant supports research to investigate the role of TDP-43 citrullination in the pathogenesis of amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The...
The National Institute on Aging (NIA), under the Aging Research Federal Grant Program (CFDA 93.866), awarded a $228,019 Project Grant to Acrobat Genomics, Inc. The grant supports the development of a high-throughput protein engineering platform (ACROBATX) to enhance the company's proprietary ARGN gene editing system. The goal is to create a new gene therapy for amyotrophic lateral sclerosis (ALS), a fatal neurological disease, by optimizing the ARGN system to deplete expression of the mutant...
This federal Project Grant award of $238,500 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will support research conducted by the University of California, San Diego (UCSD) to develop a new phosphorodiamidate morpholino oligonucleotide (PMO) therapeutic for treating Alzheimer's disease (AD). The research aims to create a highly effective PMO that can...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, will fund research to investigate the role of proton-mediated signaling at the neuromuscular junction in amyotrophic lateral sclerosis (ALS) models. The $387,525 award to the Board of Regents of the Nevada System of Higher Education, operating through the University of Nevada, Reno, will...
This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is supporting research to investigate the role of the deubiquitylation pathway in TDP-43 pathology associated with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The $460,625 award, with a project period from June 7, 2025 to May 31, 2027, will enable the University...